Withings’ ScanWatch has acquired FDA clearance, paving the best way for it to be offered within the US beginning in November, the corporate introduced. The watches, obtainable in common and diver-style Horizon variations, have concurrently been cleared to take electrocardiogram (ECG) and SpO2 (oxygen saturation) readings, in well being and medical settings.

The authentic ScanWatch has been obtainable in Europe because it got here out a yr in the past, however FDA clearance has taken for much longer. Both fashions use ECG readings to examine for atrial fibrillation (heartbeat irregularities), and you’ll even obtain the outcomes and mail them to your physician as a PDF. If it notices any irregular heartbeats, it is going to advise you to take an ECG take a look at. 

We discovered the ScanWatch to be the most effective hybrid smartwatch on the market, providing a conventional analog watch look and a small PMOLED show to show actions, heartrate, ECG, SpO2 and extra. As with Withings’ scales and different well being units, it really works with the corporate’s Health Mate app. 

Sales will start in early November 2021, with costs beginning at $279 for the unique ScanWatch 38mm mannequin. The Rose Gold and Horizon variations will shall be obtainable in early 2022 priced from $299 and $499 respectively.